📋 Clinical Overview

Lidocaine (2%) is a widely used amide-type local anesthetic agent, primarily employed for surface anesthesia, infiltration, and nerve block. It stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, thereby producing local anesthetic, antiarrhythmic, and anticonvulsant effects. In the Indian market, it is a cornerstone drug for minor surgical procedures, dental work, and topical analgesia.

💊 Dosage & Administration

Adult: Dose varies by procedure and site. Maximum recommended dose without epinephrine: 4.5 mg/kg (not to exceed 300 mg). With epinephrine: 7 mg/kg (not to exceed 500 mg). For infiltration: 1-5 mL (20-100 mg) of 2% solution. For nerve block: 1-30 mL (20-600 mg) depending on the nerve.

Note: For injection: Use aseptic technique. Aspirate before injection to avoid intravascular administration. Inject slowly. For topical use: Apply to clean, dry mucous membrane as a spray, gel, or solution. Do not swallow topical preparations meant for oral mucosa. Never inject into infected or inflamed tissue.

⚠️ Contraindications

Known hypersensitivity to lidocaine, other amide-type local anesthetics, or any component of the formulation.
Patients with Adam-Stokes syndrome, severe degrees of sinoatrial, atrioventricular, or intraventricular block (in the absence of a pacemaker) when used as an antiarrhythmic.
Septicemia at the proposed injection site.
Local infection at the proposed injection site.

🔬 Mechanism of Action

Lidocaine acts by blocking voltage-gated sodium channels in the neuronal cell membrane. It binds preferentially to activated and inactivated channels, stabilizing them in their inactive state. This prevents the transient increase in sodium ion permeability required for the depolarization phase of the action potential, thereby halting the initiation and propagation of nerve impulses.

🤕 Side Effects

Transient burning or stinging at application site.
Localized erythema or edema.
Numbness beyond the target area.
Mild dizziness or lightheadedness.

🤰 Special Populations

Pregnancy: Category B (US FDA). Animal studies show no risk, but adequate human studies are lacking. Use only if clearly needed, especially in the first trimester. Consider that lidocaine crosses the placenta. Use lowest effective dose for required procedures.

Driving: Patients should be advised not to drive or operate machinery until the effects of numbness and any potential systemic effects (like dizziness) have completely worn off.

🔄 Drug Interactions

Beta-blockers (e.g., Propranolol)	Decreased hepatic clearance of lidocaine, increasing risk of toxicity.	Major
Cimetidine	Inhibits CYP enzymes, reduces lidocaine metabolism, increases plasma levels and toxicity risk.	Major
Class I Antiarrhythmics (e.g., Mexiletine, Tocainide)	Additive cardiac effects, increased risk of arrhythmias and toxicity.	Major
CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin)	Increased lidocaine levels.	Moderate
CYP1A2 Inducers (e.g., Smoking, Omeprazole)	May decrease lidocaine levels.	Moderate
Succinylcholine	Lidocaine may enhance neuromuscular blockade.	Moderate
Vasoconstrictors (e.g., Epinephrine in formulation)	Prolongs duration, reduces systemic absorption. Contraindicated in areas with end-arteries (fingers, toes, penis, ears).	Moderate

Lignox